Votan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Votan

Property Description
Active Ingredient Diclofenac (Sodium or Potassium salt)
Primary Forms Tablets, Gels, Solutions, Suppositories
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Purpose Reduces pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Votan (Diclofenac)?

Votan is a trade name for a medicine containing the active ingredient Diclofenac, which is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This core compound is a synthetic derivative of phenylacetic acid and is typically formulated as the Diclofenac sodium or Diclofenac potassium salt, serving as a single-active ingredient product. Its NSAID categorization is based on its fundamental action as a Cyclooxygenase (COX) inhibitor, interrupting the body's biochemical processes that drive inflammation. Diclofenac's classification is based on its ability to inhibit prostaglandin synthesis. This means the drug works by blocking the core pathway responsible for initiating pain signals and swelling, a mechanism recognized for the management of inflammatory conditions.

Common Forms and General Purpose

The medicine containing Diclofenac is available in multiple dosage forms, allowing for targeted or systemic delivery via different routes of administration. These preparations include oral tablets and capsules, topical gels and creams for cutaneous application, rectal suppositories, and sterile solution preparations for parenteral (injectable) use. This wide array of pharmaceutical preparations enables flexibility in application based on the required speed and site of action. The general therapeutic purpose of this NSAID is the simultaneous control of three physiological responses: providing relief from pain (analgesia), reducing swelling and redness (anti-inflammatory), and normalizing an elevated body temperature (antipyresis). The medicine is utilized for these three therapeutic purposes and is primarily used to manage conditions characterized by noticeable inflammation and associated discomfort.

What side effects are possible with Votan?

Votan: Possible Side Effects and Safety Information

This information is based on the official safety documentation and regulatory data for this medicine. It provides the formally documented adverse reactions and safety limitations.


Adverse Reactions and Frequencies

Adverse reactions associated with Votan are officially classified based on the System Organ Class (SOC) affected and the frequency of their occurrence, utilizing a standardized five-tier system (e.g., Very Common, Common, Uncommon, Rare, Very Rare, and Not Known). This classification allows for a regulated assessment of the drug’s overall risk profile.

Classification Incidence in Regulatory Documents
Very Common Occurs in ge 1 in 10 patients
Common Occurs in ge 1 in 100 to <1 in 10 patients
Uncommon Occurs in ge 1 in 1,000 to <1 in 100 patients
Rare Occurs in ge 1 in 10,000 to <1 in 1,000 patients

Serious Adverse Events and Limitations

Serious adverse reactions documented in official sources are medical events that result in hospitalization, are life-threatening, or lead to significant disability, and are highlighted regardless of their frequency. The regulatory label includes formal Contraindications, which specify patient conditions or concurrent uses where the medicine must not be administered due to unacceptable risk.

Population-Specific Safety: Documentation may include specific safety considerations for patients with certain pre-existing conditions, such as hepatic or renal impairment, or for distinct age groups. Safety-related restrictions also cover necessary monitoring requirements (e.g., laboratory testing) specified in official labeling to manage risks proactively.


Regulatory Safety Summary

The medicine's safety profile is formally structured by government authorities to categorize known risks by physiological impact (SOC), likelihood (Frequency Classification), and severity (Serious Adverse Reactions). This mandated framework defines the official risk landscape and ensures consistent, standardized reporting of all safety information.

Overdose and Emergency Response

Overdose and When to Seek Help

A drug overdose occurs when a toxic, or excessive, amount of a substance is present in the body, overwhelming its normal functions and potentially leading to serious health risks. Although specific overdose information for the drug Votan is not widely detailed in common authoritative summaries, all suspected overdoses should be treated as a medical emergency.

Clinical Manifestations of Overdose

General overdose symptoms vary significantly based on the type and amount of substance ingested, the individual's health, and whether other substances were taken. General signs of severe drug toxicity that warrant immediate attention include:

System Manifestation
Central Nervous System Confusion, extreme drowsiness, loss of consciousness, unresponsiveness, or seizures.
Cardiopulmonary Slow, shallow, or stopped breathing; erratic or weak pulse; blue or pale lips and fingernails.
General Vomiting (especially while unconscious), limp body, or uncoordinated movement.

Required Emergency Action

Urgent medical attention is required immediately if an overdose of Votan or any other substance is suspected. The general medical recommendation is to contact emergency services (e.g., 911 or local equivalent) or a poison control center right away. Do not attempt to induce vomiting or allow the affected person to 'sleep it off'.

Be prepared to provide the name of the product, the estimated amount taken, and the time of ingestion to medical professionals. Quick intervention is critical to stabilize vital functions and prevent potential long-term complications such as respiratory failure, brain damage, or death.

Therapeutic Uses of Votan

This medication may be considered relevant for easing symptomatic discomfort across several key therapeutic domains.

Votan is commonly used to help with symptom clusters that may become intense or disruptive in chronic conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied across domains where additional symptomatic support is needed to address the persistent pain, stiffness, and localized swelling of affected joints. This support may assist with maintaining better functional stability and contributes to improved comfort during periods of heightened symptoms.

The medicine is applied for supportive symptomatic assistance in contexts where physical manifestations are sudden and intense. This includes managing pain and inflammation arising from acute tissue damage, such as sprains, strains, and contusions, and may be used for short-term assistance in managing discomfort and inflammation related to post-operative procedures or inflammatory flares like an acute gout attack. Additionally, Votan may be relevant for easing challenging symptoms associated with episodic pain syndromes, such as the acute management of migraine headaches and may assist with the management of pronounced symptoms during primary dysmenorrhea (severe menstrual cramping). It provides support that helps ease the overall symptom burden when symptoms interfere with routine activities.

“This support contributes to easing the overall symptom load when symptoms interfere with routine activities.”


Quick Fact: Relief for Inflammatory Pain

  • Votan is commonly used to help manage symptoms related to inflammatory or irritative states, such as pain, tenderness, and swelling.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Votan?

Eligibility to use Votan (Diclofenac) is defined by official regulatory bodies and depends on pre-existing medical conditions and specific population criteria. The following rules are based on regulatory prescribing information and define absolute prohibitions for use.


Absolute Contraindications (Do Not Use)

Individuals who must not use Votan include patients with:

  • Hypersensitivity or allergy to Diclofenac, Aspirin, or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).
  • Active gastrointestinal bleeding, peptic ulceration, or a history of recurrent perforation.
  • Severe, uncontrolled heart failure (e.g., NYHA Class II-IV), established ischemic heart disease, or cerebrovascular disease.
  • Severe hepatic (liver) failure or severe renal (kidney) failure.
  • Third trimester of pregnancy.
  • Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Age and Population Restrictions

Population Group Regulatory Status
Adults (18+ years) Use is generally established and permitted for approved indications.
Pediatric Patients Safety and effectiveness are not established for most forms in children and adolescents under 18; age cutoffs vary by formulation.
Geriatric Patients Use requires caution and the lowest effective dose due to increased risk of serious adverse events.
Pregnancy/Lactation Contraindicated in the third trimester. Not recommended during breastfeeding.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Votan (Diclofenac)

The official interaction profile for Votan is classified by regulatory authorities based on pharmacokinetic exposure changes and pharmacodynamic risk reinforcement.


Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions NSAIDs, Anticoagulants, Antiplatelet agents, SSRIs, Systemic Corticosteroids, Diuretics, ACE Inhibitors, ARBs, Beta-Blockers, Food, Alcohol.
Specific interacting medicines (if explicitly listed) Aspirin (Analgesic doses), Voriconazole, Digoxin, Furosemide.
Interaction-related restrictions Use is contraindicated for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant systemic NSAIDs should be avoided.

Resulting Interaction Structure

Official regulatory documents specify that co-administration with Voriconazole is a pharmacokinetic interaction that measurably increases the plasma concentration (Cmax and AUC) of Diclofenac. A pharmacodynamic interaction results in a heightened risk of ulceration and bleeding when combined with Anticoagulants, SSRIs, or Systemic Corticosteroids. Additionally, Votan may diminish the antihypertensive or natriuretic effect of medicines such as ACE Inhibitors, ARBs, and Diuretics. This interaction structure is particularly relevant in elderly or renal impaired patients, where the renal risk with ACE Inhibitors or ARBs may be intensified. Furthermore, alcohol use increases the risk of gastrointestinal bleeding, and the oral solution form must be taken on an empty stomach to prevent a documented reduction in effectiveness.

Mechanism of Action

Votan's mechanism centers on the competitive inhibition of the Cyclooxygenase (COX) enzymes, a core action that modulates key signaling pathways responsible for regulating nociception, thermal homeostasis, and vascular permeability.


u1f52c Molecular Blockade of COX Enzymes

The primary action involves blocking both the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This molecular blockade prevents the necessary conversion of the endogenous substance Arachidonic Acid into signaling molecules called Prostaglandins ( PGs). This step modifies early molecular processes that shape systemic physiological outcomes by reducing the chemical supply of these prostaglandin mediators.


u1f321️ Restriction of Physiological Signal Magnitude

By reducing the synthesis of PGE2 and PGI2, the mechanism acts to restrict the magnitude of signal amplification at both peripheral and central sites. In the periphery, this leads to reduced PG-mediated nociceptor sensitization and less PG-driven vasodilation. In the central nervous system, this PG reduction in the hypothalamus supports the regulation of the thermal set point. This dual-site modulation leads to adjustments in physiological responses that define the drug's mechanistic profile.

Dosage and Administration Information

The administration of Votan (Diclofenac) follows established specifications outlining the official route, dosage, and frequency patterns. The medicine is approved for Oral administration in forms including Immediate-Release (IR), Delayed-Release (DR), Extended-Release (ER) tablets, and a powder for oral solution. It is also approved for Topical, Rectal, and Parenteral (Intramuscular and Intravenous) routes.

Official Dosing and Frequency

Standard oral dosing for chronic conditions often ranges from 100 mg to 200 mg per day, typically taken in divided doses two to four times daily for IR/DR forms, or once daily for the ER formulation. Acute use regimens may involve a lower daily maximum, with single doses typically around 50 mg. Established guidelines specify that the lowest effective dosage for the shortest duration possible must be used across all applications, and parenteral use is generally limited to a maximum of two days.

Administration Conditions

Specific instructions relate to the form used: Delayed-Release tablets must be swallowed whole and must not be crushed, split, or chewed to preserve the formulation's design. The oral powder must be mixed with water only and should be consumed on an empty stomach for proper use. For topical administration, the guideline is to use the enclosed dosing card to ensure accurate application. Dosing protocols also recommend the lowest possible dose for older or frail adult patients. In the event of a missed dose, the guidance is to skip the missed dose and resume the regular schedule; a dose must not be doubled.

Recent Clinical Evidence

Votan (Disitamab Vedotin, RC48) is an antibody-drug conjugate (ADC) specifically targeting the Human Epidermal Growth Factor Receptor 2 (HER2), an important biomarker in several types of cancer. Recent clinical trials have focused on evaluating its efficacy and safety, particularly in advanced or metastatic solid tumors that express HER2.

Efficacy in Urothelial Carcinoma

Clinical evidence from combined analyses of Phase II, open-label, multicenter, single-arm studies has demonstrated promising anti-tumor activity for Votan in patients with HER2-positive locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed after at least one prior line of systemic chemotherapy. The pooled analysis reported an objective response rate (ORR) of approximately 50.5% in this patient population. The median duration of response was observed to be around 7.3 months, with median progression-free survival (PFS) at 5.9 months and overall survival (OS) at 14.2 months. These findings support its therapeutic potential in this setting, including in subgroups previously treated with anti-PD-1/L1 therapies.

Ongoing Research Areas

Investigation into Votan’s role continues in various oncology settings. Ongoing clinical trials are exploring its use, often in combination with immunotherapy agents, for other HER2-expressing solid tumors. These include studies on:

Area of Investigation Study Phase/Design
HER2-low, HR-positive Breast Cancer Phase II, Single-Arm, Neoadjuvant Setting
Cisplatin-intolerant Bladder Urothelial Carcinoma Phase I/II, Combination Therapy, Neoadjuvant Setting

Safety Profile

The safety profile observed in clinical trials is generally manageable. The most common treatment-related adverse events reported in the metastatic urothelial carcinoma studies included peripheral sensory neuropathy, leukopenia, increased liver transaminases (AST), and neutropenia. Grade 3 or higher treatment-related adverse events occurred in over half of the patients, highlighting the need for careful patient monitoring and management of side effects.

Frequently Asked Questions (FAQ)

Common questions about Votan (FAQ)

Q: What is Votan actually used for, besides the main thing mentioned?

A: According to official product information, Votan (Diclofenac) is approved for a variety of conditions related to pain and inflammation. This includes treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as relief for acute pain, ankylosing spondylitis, and primary dysmenorrhea (menstrual cramps).


Q: Does taking Votan require any special diet changes?

A: Regulatory documents specify that certain Votan formulations must be taken on an empty stomach for proper use. While specific diet changes are generally not required, official warnings exist regarding the combination of Votan with certain medications that can increase potassium levels, which may require limiting potassium-rich foods.


Q: Can Votan be taken with vitamins or herbal supplements?

A: Official regulatory guidance advises caution regarding co-administration of Votan with other substances that could increase the risk of side effects like gastrointestinal bleeding or affect renal function. There are also specific warnings concerning the use of medicines that increase potassium levels, a consideration that may apply to certain vitamins or herbal supplements.


Q: What kind of studies were done to get Votan approved?

A: The regulatory approval for Votan is based on clinical trials that demonstrated the medicine's effectiveness in reducing pain and improving physical function in patients with inflammatory conditions. Official labeling often includes a summary of these studies, which established its efficacy profile for the approved indications.


Q: What is the success rate of Votan in clinical trials?

A: Studies and official information indicate that Votan demonstrated efficacy in clinical trials by helping to improve joint function and reduce pain in conditions like rheumatoid arthritis. The full response rates and specific measures of success are detailed within the clinical pharmacology sections of the medicine's regulatory label.


Q: How often do the serious side effects of Votan occur?

A: According to the official product information, all medicines in Votan's class carry a Black Box Warning because of the risk of serious side effects, including cardiovascular events (like heart attack or stroke) and gastrointestinal bleeding. These events can occur at any time during use, and the overall risk is generally regarded as increasing with higher doses and longer durations of treatment.


Q: How is Votan eliminated from the body?

A: Official regulatory documents describe Votan's elimination process, stating that the medicine is primarily cleared through metabolism in the liver. The resulting compounds (metabolites) are then excreted from the body via both the urine and the bile. The terminal half-life of the unchanged medicine is approximately 2 hours.


Q: What is the maximum duration I can take Votan for?

A: Regulatory guidance advises that Votan should be used at the lowest effective dose for the shortest duration possible to manage the condition. While the official label does not provide a specific maximum duration for chronic treatment, it indicates that the risk of serious side effects generally increases with higher doses and longer overall treatment periods.


Q: How does Votan affect lab test results?

A: According to official product information, prolonged treatment with Votan may cause significant elevations (more than three times the upper limit of normal) in liver enzymes such as AST and ALT in some patients. Because of this, regulatory documents specify the necessity of monitoring liver function during long-term use.


Q: How quickly does Votan typically start to work?

A: Regulatory documents indicate that Votan is rapidly absorbed, with peak levels in the blood usually reached within 2 to 2.5 hours for the sodium salt formulation. The full therapeutic effect of the medicine for chronic conditions may typically be seen within one week, though individual response times can vary.


Q: Is it common to feel tired when first starting Votan?

A: Yes, official product information lists tiredness, dizziness, and drowsiness as known side effects associated with Votan. These effects may be mild, particularly when starting treatment.


Q: Are there any long-term effects of taking Votan for many years?

A: Regulatory documents clearly state that long-term continuous use of Votan significantly increases the risk of serious side effects. These include an elevated risk of cardiovascular events (such as heart attack or stroke), as well as increased risk of gastrointestinal bleeding and adverse effects on the kidneys and liver.


Q: Does Votan cause weight gain or weight loss?

A: Official product information lists edema (fluid retention or body swelling) as a potential adverse reaction to Votan. While weight change itself is not typically listed as a primary side effect, fluid retention can sometimes contribute to changes in body weight.


Q: Can Votan affect my sleep patterns?

A: Yes, regulatory documents list drowsiness as a known side effect that may affect sleep patterns. Changes in mood or other central nervous system effects are also sometimes reported.


Q: How long does Votan stay in your system after you stop taking it?

A: According to the official product information, Votan has a short terminal half-life of approximately 2 hours. This is the time required for the concentration of the medicine in the bloodstream to decrease by half.


Q: Are the side effects of Votan permanent?

A: Official regulatory information indicates that many of the milder and more common side effects, such as stomach upset or drowsiness, are often temporary and tend to lessen as the body adjusts to the medicine. However, serious adverse events carry the potential for long-term complications.


Q: Can Votan make me feel dizzy or lightheaded?

A: Yes, official product information lists dizziness and vertigo (a sensation of spinning or whirling) as known side effects of Votan. Patients who experience this effect are advised to use caution.


Q: Can Votan affect fertility or family planning?

A: Regulatory documents indicate that caution is advised for women who are attempting to conceive. This is because non-steroidal anti-inflammatory drugs (NSAIDs) can potentially cause reversible infertility in some cases, and discontinuation should be considered.


Q: Are there any specific warning signs I should look out for while on Votan?

A: Regulatory documents highlight specific warning signs that are considered medical emergencies. These include symptoms of serious skin reactions, such as fever, rash, blistering, or peeling skin, as well as signs of gastrointestinal bleeding, such as black or tarry stools.


Q: Is it true that Votan is only for severe cases?

A: The medicine is approved for the management of both acute (short-term) and chronic (long-term) pain and inflammation. Regulatory documents list indications that include mild-to-moderate conditions like osteoarthritis, indicating that use is not limited strictly to severe cases.


Q: Does Votan affect my ability to drive or operate machinery?

A: Official regulatory documents advise caution regarding driving or operating machinery while taking Votan. This is due to known side effects that can affect physical and mental alertness, such as feelings of tiredness, dizziness, drowsiness, and potential problems with eyesight.


Q: Can Votan cause skin rashes or itching?

A: Yes, official product information lists skin reactions such as rash, itching, and hives as known side effects. Regulatory documents also caution that severe, potentially life-threatening skin reactions, though rare, have been reported with this class of medicine.


Q: Are there any known issues with Votan and dental procedures?

A: Votan is sometimes prescribed for short-term pain relief, such as following dental surgery. Its use in the period immediately surrounding any surgical procedure requires careful consideration due to the medicine's effects on blood clotting and bleeding time.


Q: Are there any genetic factors that influence how Votan works?

A: Regulatory documents and scientific literature indicate that genetic factors can influence how Votan works in the body. Its clearance depends heavily on the activity of the liver enzyme CYP2C9, and individuals may have known genetic variations that affect this enzyme's function.


Q: Are the initial side effects of Votan temporary?

A: Official regulatory information indicates that many common side effects, such as mild stomach upset, indigestion, or drowsiness, are often temporary. These effects may decrease in intensity or fully resolve after the body has adjusted to the medicine.


Q: Does Votan interact with hormonal birth control?

A: According to official product information, Votan is generally not known to reduce the effectiveness of oral contraceptives. However, an interaction is noted when Votan is combined with birth control containing the ingredient drospirenone, which may increase the risk of developing hyperkalemia (high potassium levels).


Q: Is Votan safe for people with diabetes?

A: Regulatory documents indicate that caution is advised for individuals with diabetes, particularly when Votan is combined with certain interacting medications. This is because they may be at a higher risk of developing hyperkalemia (high potassium levels) due to the drug combination.

How should Votan be stored and disposed of?

Storage and Protection Requirements

Official regulatory labeling dictates that Votan (Diclofenac) tablets and suppositories must generally be stored at or below a specific temperature maximum (e.g., 25 C or 30 C) to maintain stability. All forms require protection from excessive heat and humidity, and topical gel must be kept in the original container to protect from light. It is a mandatory labeled instruction that the medicine must be stored strictly out of the sight and reach of children.

Disposal and Handling Rules

Unused or expired Votan should be disposed of by taking it to an authorized drug take-back program. If no program is available, the FDA's guidance requires mixing the medicine with an undesirable substance (e.g., dirt) and sealing it before discarding it in the household trash. The regulatory profile notes that Diclofenac poses a risk to the aquatic environment, meaning it must not be thrown into wastewater or ordinary household waste, and disposal must follow local requirements. Topical gel has a specific handling warning: do not smoke or go near naked flames during use due to fire risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Votan found in:

A-Z Index: